论文部分内容阅读
多发性骨髓瘤(MM)是一种少见(约5/10万)而多发于老年人(中位年龄65岁)的恶性肿瘤。采用标准方案即用马法兰和泼尼松,虽然50％患者获得缓解,但即使加用了其它烷化剂或阿霉素,其中位生存期仍只有3年。过去把MM视为有终末B细胞表型的单克隆体瘤细胞增殖,近5年来则从为MM细胞衍生于极未成熟的具有多向分化潜能的造血祖细胞,故近年来对大剂量化疗伴或不伴造血干细胞支持能否克服耐药或在疾病早期应用能否延长缓解
Multiple myeloma (MM) is a rare (about 5 / 100,000) malignancy that occurs in the elderly (median age 65 years). With standard regimens of melphalan and prednisone, median survival was only 3 years, even with the addition of other alkylating agents or doxorubicin, although 50% achieved remission. In the past, the proliferation of monoclonal tumor cells with MM as a terminal B-cell phenotype has been derived from MM cells for extremely immature mature hematopoietic progenitor cells with multi-directional differentiation potential in recent 5 years. Therefore, in recent years, Chemotherapy with or without hematopoietic stem cell support can overcome drug resistance or early application of the disease can prolong remission